Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE-Immunotherapeutics_resized
OSE Immunotherapeutics (PAR: OSE) – Combi-TED earns ESMO oral presentation
Published by Arron Aatkar, PhD

OSE Immunotherapeutics has announced that topline results from the Phase II Combi-TED study of Tedopi in second-line metastatic non-small cell lung cancer have been selected for a rapid oral presentation at ESMO 2026, on 25 October. The randomised, three-arm study enrolled 105 HLA-A2-positive patients following progression on first-line chemo-immunotherapy and evaluates lead cancer vaccine asset, Tedopi, in combination with nivolumab or docetaxel against docetaxel alone. The primary endpoint is the one-year survival rate, making the presentation an important clinical readout for Tedopi’s positioning in the post-chemo-immunotherapy setting. No efficacy or safety results have been disclosed at this stage, so investor focus will be on the magnitude and consistency of the survival signal when the full topline data are presented.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.